Merck kicks off Hope Against Hepatitis C initiative
WHITEHOUSE STATION, N.J. — Drug maker Merck announced that it has kicked off an initiative that includes a wide range of public education and patient support programs, as well as research efforts to help improve care for people living with chronic hepatitis C virus infections.
Merck’s Hope Against Hepatitis C initiative includes a variety of public-private partnerships, educational programs and collaborative research efforts aimed at supporting the hepatitis C community.
The drug maker also has launched a new consumer education website, AllAboutHepC.com, to help inform patients about the risks associated with chronic HCV infection and to address common questions about the disease.
"Winning the battle against viral hepatitis C requires improved public awareness and education to ensure that those at risk speak to their physicians about getting tested," said Patrick Bergstedt, SVP and general manager, infectious diseases, global human health at Merck. "Merck is committed to supporting these efforts, which are critical to managing this serious public health issue.”
No comments found
Sanofi bids adieu to Aventis moniker
PARIS — French drug maker Sanofi-Aventis has shortened its name to Sanofi, the company said.
The company, which acquired Cambridge, Mass.-based biotech giant Genzyme for $20.1 billion earlier this year, had planned to vote at its shareholder meeting Friday.
According to published reports, the previous name was difficult to pronounce for people in many countries.
No comments found
Napo sues Salix over breach of collaboration agreement commitments
RALEIGH, N.C. — Napo Pharmaceuticals has filed a lawsuit against Salix Pharmaceuticals, alleging that the latter breached commitments under an agreement to develop and commercialize a proprietary gastrointestinal compound.
Salix said that Napo’s claims over its collaboration agreement concerning the development of crofelemer are without merit, adding that the drug maker plans to continue with the development and commercialization of crofelemer, in accordance with its past guidance and the terms of its collaboration agreement with Napo.
Crofelemer is Napo’s lead drug candidate, according to the company’s website, and is under development for gastrointestinal indications, including chronic diarrhea in patients living with HIV/AIDS.
Hopefully they can both work together to create a better drug than either could make individually. This is going to be a tough case. http://allherbalremedies.org/chronic-diarrhea-causes-treatment/